Quarterly report pursuant to Section 13 or 15(d)

11. SEGMENTS (Details)

v3.8.0.1
11. SEGMENTS (Details) - USD ($)
 3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Revenues $ 4,042,006 $ 2,628,871
Cost of product revenue 12,242,748 1,616,287
Loss from operations (16,532,503) (5,937,003)
Other expense, net (1,289,639) (599,960)
Net loss (17,822,142) (6,536,963)
Total assets 91,137,625 17,594,918
Depreciation and amortization expense 829,541 118,062
Capital expenditures 829,541 3,584
ADMA BioManufacturing    
Revenues 1,666,243 0
Cost of product revenue 10,697,642 0
Loss from operations (12,724,718) 0
Other expense, net (240,054) 0
Net loss (12,964,772) 0
Total assets 47,481,781 0
Depreciation and amortization expense 105,199 0
Capital expenditures 631,832 0
Plasma Collection Center Member    
Revenues 2,340,055 2,593,163
Cost of product revenue 1,545,106 1,616,287
Loss from operations (1,038,824) (502,600)
Other expense, net (435) 0
Net loss (1,039,259) (502,600)
Total assets 27,532,613 2,286,500
Depreciation and amortization expense 444,047 103,640
Capital expenditures 188,914 2,084
Corporate Member    
Revenues 35,708 35,708
Cost of product revenue 0 0
Loss from operations (2,768,961) (5,434,403)
Other expense, net (1,049,150) (599,960)
Net loss (3,818,111) (6,034,363)
Total assets 16,123,231 15,308,418
Depreciation and amortization expense 0 14,422
Capital expenditures $ 8,795 $ 1,500